Latest news about Amrutanjan Health Care
Amrutanjan Health Care
524.10
+6.25(+1.21%)
Company Performance:
View Company Insights1D+1.21%
1M-1.39%
6M-17.47%
1Y-22.12%
5Y-23.49%
More news about Amrutanjan Health Care
14May 26
Amrutanjan FY26 PAT Rises 14%; Board Recommends Dividend
Amrutanjan Health Care reported a 14% rise in FY26 profit after tax to INR 5,791.78 lakhs, driven by revenue growth to INR 50,255.27 lakhs. Q4 EBITDA surged to INR 2,862.12 lakhs with margins expanding to 19.12%. The board recommended a final dividend of INR 2.90 per share and approved director appointments.
09May 26
Amrutanjan Health Care Gains 44,000 New Chemists, Targets 100,000 by September FY27
Amrutanjan Health Care has onboarded 44,000 new chemists as part of its distribution expansion drive. The company has set a target of reaching 100,000 chemists by September FY27, aiming to significantly broaden its pharmacy retail network. This initiative reflects the company's strategic focus on strengthening last-mile distribution and enhancing product accessibility across India.
09May 26
Amrutanjan Health Care Approves Revised Second Phase ESOP 2 Under Employee Stock Option Scheme 2020
Amrutanjan Health Care Limited's Board approved the revised Second Phase ESOP 2 under its Employee Stock Option Scheme 2020 on May 8, 2026, covering 2,00,000 equity shares for 44 top and middle management employees. The grant price was set at Rs. 502.00, derived after applying a 10% discount to the closing NSE market price of Rs. 558.00 on May 7, 2026, with vesting conditions tied to sales targets across FY27 to FY31 and a last exercise window of October 2031.
30Apr 26
Amrutanjan Health Care Limited Announces Board Meeting on May 8, 2026 for Q4FY26 Results and Dividend Recommendation
Amrutanjan Health Care Limited has scheduled a board meeting for May 8, 2026, to approve audited financial results for Q4FY26 and recommend final dividend for FY2025-26. The meeting will be conducted via video conferencing in compliance with SEBI regulations. The company has maintained trading window restrictions from April 1 to May 10, 2026, as per insider trading regulations.
17Apr 26
Amrutanjan Health Care Launches New Product Range in Personal Care, Wound Care and Pain Management
Amrutanjan Health Care Limited announced on 17 April 2026 the launch of a comprehensive new product portfolio spanning Personal Care, Wound Care, and Pain Management categories. The Personal Care segment includes three razor variants under the Comfy and Smoother brands, developed using Korean technology, with price points ranging from ₹ 50 to ₹ 100. In the Wound Care category, the company introduced Amrutanjan Plastry, a medicated antiseptic plaster range available in Regular and Wash proof variants in a jar format. The Pain Management portfolio expanded with the launch of Amrutanjan Ortho Pain Relief + Oil, featuring advanced heat therapy formulation with Gandhapura and Capsaicin, clinically proven to provide up to 66% pain reduction in 8 weeks. All products are targeted at the domestic market.
17Apr 26
Amrutanjan Health Care Rephrases Second Phase of Employee Stock Option Scheme
Amrutanjan Health Care Limited has rephrased the Second Phase ESOP 2 of its existing Employee Stock Option Scheme 2020, with approval from the Nomination and Remuneration Committee on April 17, 2026. The company informed stock exchanges about this development under SEBI regulations, maintaining compliance with listing obligations and disclosure requirements.
08Apr 26
Amrutanjan Health Care Submits Q4FY26 Compliance Certificate Under SEBI Regulations
Amrutanjan Health Care Limited submitted its Q4FY26 compliance certificate under SEBI (Depository Participants) Regulations on April 08, 2026. The certificate, issued by registrar Cameo Corporate Services Limited, confirms proper handling of dematerialised securities for the quarter ended 31/03/2026. The filing demonstrates the company's adherence to regulatory requirements for securities processing and depository participant regulations.
18Mar 26
Amrutanjan Health Care Receives Rs 24.28 Lakh GST Demand Order, Plans Appeal
Amrutanjan Health Care Limited received a Rs 24.28 lakh tax demand order under CGST/IGST Act 2017 from tax authorities on March 17, 2026, related to alleged input tax credit violations during 2020-21 to 2021-22. The company disagrees with the order citing proper compliance with GST law conditions and plans to file an appeal. Management believes the order will not have major financial implications on company operations.
18Mar 26
Amrutanjan Health Care Responds to NSE Surveillance Query on Court Order and News Article
Amrutanjan Health Care Limited responded to NSE surveillance queries regarding a news article and court order, clarifying that no negotiations were taking place and the news referred to an old 2005 case decided by Madras High Court. The company received the court order copy on 17 March 2026 and confirmed no material impact on business operations, with the matter already disclosed as contingent liability in annual reports.
03Feb 26
Amrutanjan Health Care Q3 Results: EBITDA Grows to ₹252M, Margin Declines YoY
Amrutanjan Health Care's Q3 results show EBITDA growth to ₹252M from ₹234M year-over-year, but EBITDA margin compressed to 17.85% from 19.02%. The company achieved revenue growth to ₹1.4B and maintained net profit at ₹195M, with board meeting held on February 3, 2026, for results review and interim dividend consideration.
11Nov 25
Amrutanjan Health Care Reports 7.08% Revenue Growth in Q2, Driven by Strong Pain Management Segment
Amrutanjan Health Care's Q2 results show a 7.08% YoY increase in revenue to Rs. 117.70 crores. Profit before tax grew by 20.51% to Rs. 19.21 crores, while profit after tax rose 14.23% to Rs. 15.94 crores. The pain management segment was a key growth driver, with the overall pain category growing 16%. The company plans to launch premium sanitary pads, revive the JIFFY brand, and commission a new sanitary napkin plant by late Q4. Management highlighted efforts to increase chemist channel reach and focus on market penetration in P1 markets and development in P2 markets.
10Nov 25
Amrutanjan Health Care Sets November 18, 2025 as Record Date for First Interim Dividend
Amrutanjan Health Care Limited has set November 18, 2025, as the record date for its first interim dividend of Re. 1/- per share for FY 2025-26. The company's board approved unaudited financial results for Q2 and H1 FY 2025-26, showing a 7.08% increase in revenue from operations and an 18.36% rise in profit after tax compared to the same quarter last year. The board meeting, held on November 10, 2025, lasted from 12:00 PM to 4:30 PM.
10Nov 25
Amrutanjan Health Care Reports Robust Q2 Performance with 18.4% Profit Growth
Amrutanjan Health Care Limited announced robust Q2 FY2025-26 results. Net profit increased by 18.4% to ₹139.60 crore, while revenue grew 7.1% to ₹1,177.00 crore. EBITDA rose 21.5% to ₹165.20 crore, with EBITDA margin expanding by 166 bps to 14.04%. The company declared a first interim dividend of ₹1 per share, with November 18, 2025, set as the record date.
12Aug 25
Amrutanjan Health Care Reports 80% Profit Surge, Sets AGM Date
Amrutanjan Health Care Limited announced Q1 FY2026 results with an 80% increase in profit after tax to ₹831.12 lakhs. Revenue from operations rose 12.3% to ₹9,404.57 lakhs. EPS improved to ₹2.87. OTC Products remained the largest revenue contributor. The company scheduled its 88th AGM for September 23, 2025, set September 16 as the record date, and appointed M/s. SPNP & Associates as Secretarial Auditor for five years.
15May 25
Amrutanjan Health Care Reports Strong Q4 Results, Announces Dividend
Amrutanjan Health Care's Q4 financial results show significant growth. Revenue increased by 6.30% to ₹1.35 billion, while net profit rose by 11.13% to ₹151.80 million. EBITDA improved to ₹177.00 million with a margin of 13.07%. The company also announced a final dividend of ₹2.60 per equity share, reflecting confidence in its financial position and commitment to shareholder value.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
1,940.00
(-1.22%)
8,388.00
(+0.12%)
5,000.00
(-0.60%)
1,458.80
(-0.08%)
1,121.10
(-0.79%)
2,388.00
(-0.91%)
2,435.60
(-0.10%)
1,835.00
(-0.81%)
1,176.00
(+0.29%)
1,613.40
(+1.73%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
